Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Abstract Background Sorafenib is approved as a standard therapy for advanced hepatocellular carcinoma (HCC), but its clinical application is limited due to moderate therapeutic efficacy and high incidence of acquired resistance resulted from elevated levels of SDF-1/CXCR4 axis induced by prolonged s...

Full description

Bibliographic Details
Main Authors: Ning Zheng, Weiqun Liu, Bifei Li, Huifang Nie, Jian Liu, Yunlong Cheng, Jichuang Wang, Haiyan Dong, Lee Jia
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Hepatocellular carcinoma
Sorafenib
Metapristone
SDF-1/CXCR4
PLGA-PEG
Combination therapy
Online Access:http://link.springer.com/article/10.1186/s13046-019-1216-x

Internet

http://link.springer.com/article/10.1186/s13046-019-1216-x

Similar Items